Work

Phase I dose escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients (pts) with advanced solid tumors.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.9556

Authors: Sarina A. Piha-Paul, Kamalesh K Sankhala, Alexander M. Menzies, Madhuri Dey, Julian Quiñones, Ryan T. Sowell, Prashant Nambiar, Robert Shine, Katherine Kacena, Shari Thomas, LeeAnn Ali, Neil Sankar, Tasuku Kitada, Jason J. Luke, Georgina V. Long

Institutions: The University of Texas MD Anderson Cancer Center, The University of Sydney, Melanoma Institute Australia, UPMC Hillman Cancer Center, Royal North Shore Hospital

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410818063

Cites:

Cited by: 7

Related to: 10